Comparative Pharmacology
Head-to-head clinical analysis: BRIMONIDINE TARTRATE TIMOLOL MALEATE versus LABETALOL HYDROCHLORIDE IN DEXTROSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRIMONIDINE TARTRATE TIMOLOL MALEATE versus LABETALOL HYDROCHLORIDE IN DEXTROSE.
BRIMONIDINE TARTRATE; TIMOLOL MALEATE vs LABETALOL HYDROCHLORIDE IN DEXTROSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brimonidine is a selective alpha-2 adrenergic receptor agonist that reduces aqueous humor production and increases uveoscleral outflow. Timolol is a non-selective beta-adrenergic receptor blocker that decreases aqueous humor production by inhibiting beta-2 receptors in the ciliary epithelium.
Competitive antagonist at beta-1 adrenergic receptors (cardiac) and selective alpha-1 adrenergic receptors (vascular smooth muscle). Reduces heart rate, myocardial contractility, and peripheral vascular resistance.
One drop of the fixed combination (0.2% brimonidine/0.5% timolol) in the affected eye(s) twice daily, approximately 12 hours apart.
Adult: Initial 0.5-2 mg/min IV infusion, titrate to response; typical maintenance 2-8 mg/min. Max cumulative dose 300 mg.
None Documented
None Documented
Brimonidine: ~3 hours (terminal); timolol: ~4–6 hours (terminal). Clinical context: allows twice-daily dosing for brimonidine/timolol combination.
Terminal elimination half-life: 5-8 hours (adults); 8-12 hours (elderly); 2-4 hours (children). Clinical context: half-life may be prolonged in hepatic or renal impairment.
Brimonidine: primarily renal (74% as unchanged drug); timolol: renal (20% unchanged, remainder as metabolites) and fecal (small amount).
Renal: 40-60% as unchanged drug and metabolites; biliary/fecal: ~50% as metabolites; <5% unchanged in feces.
Category A/B
Category A/B
Beta-Blocker
Alpha/Beta-Blocker